Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Mifgyne
2. Mifegyne
3. Mifeprex
4. R 38486
5. R-38486
6. R38486
7. Ru 38486
8. Ru 486
9. Ru-38486
10. Ru-486
11. Ru38486
12. Ru486
13. Zk 98296
14. Zk-98296
15. Zk98296
1. 84371-65-3
2. Mifegyne
3. Mifeprex
4. Ru-486
5. Korlym
6. Ru486
7. Ru 486
8. Mifepriston
9. Corlux
10. Ru 38486
11. Ru-38486
12. Mls000069785
13. 320t6rnw1f
14. Vgx-410c
15. Chebi:50692
16. Vgx-410
17. Nsc-759862
18. Ncgc00025179-05
19. Smr000058481
20. Mifepristonum [latin]
21. Mifepristona [spanish]
22. Dsstox_cid_3322
23. C-1073
24. Dsstox_rid_76976
25. Dsstox_gsid_23322
26. (11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propyn-1-yl)estra-4,9-dien-3-one
27. (8s,11r,13s,14s,17s)-11-(4-(dimethylamino)phenyl)-17-hydroxy-13-methyl-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-3-one
28. (8s,11r,13s,14s,17s)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
29. (8s,11r,13s,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
30. 11-(4-dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodec Ahydro-cyclopenta[a]phenanthren-3-one
31. Mifepristona
32. Mifepristonum
33. (11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-prop-1-yn-1-ylestra-4,9-dien-3-one
34. Ru486 (tetramethyl-rhodamine Conjugated)
35. Mifepristone [usan:inn:ban]
36. Hsdb 6841
37. Sr-01000076011
38. R 38486
39. Brn 5779404
40. Unii-320t6rnw1f
41. Pictovir
42. Ru 486-6
43. Ccris 9332
44. 1nhz
45. 11beta-(p-(dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
46. Mifeprex (tn)
47. Pictovir (tm)
48. Prestwick_570
49. Cas-84371-65-3
50. Korlym (tn)
51. 2w8y
52. Mifepristone (mifeprex)
53. Opera_id_562
54. Mifepristone, >=98%
55. Prestwick0_000299
56. Prestwick1_000299
57. Prestwick2_000299
58. Prestwick3_000299
59. Spectrum5_002045
60. Mifepristone [mi]
61. Mifepristone [inn]
62. Mifepristone [jan]
63. Mifepristone [hsdb]
64. Mifepristone [usan]
65. 11beta-(4-(dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-on
66. 17-beta-hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oestra-4,9-dien-3-one
67. Mifepristone [vandf]
68. Bidd:pxr0123
69. Lopac0_000801
70. Schembl16087
71. Bspbio_000238
72. Mifepristone [mart.]
73. 11beta-(4-(dimethylamino)phenyl)-17-hydroxy-21-methyl-19-nor-17alpha-pregna-4,9-dien-20-m-3-on
74. 11beta-(4-(n,n-dimethylamino)phenyl)-17alpha-(prop-1-ynyl)-delta4,9-estradiene-17beta-ol-3-one
75. Mls001074115
76. Mls001424271
77. (non-labelled)mifepristone-d3
78. Mifepristone [usp-rs]
79. Mifepristone [who-dd]
80. Spbio_002457
81. Ru-486; Mifepristone
82. Bpbio1_000262
83. Chembl438575
84. Gtpl2805
85. Mifepristone (jan/usan/inn)
86. Chembl1276308
87. Dtxsid5023322
88. Bdbm18627
89. Hms1568l20
90. Hms2052l05
91. Hms2090l22
92. Hms2095l20
93. Hms2230p21
94. Hms3262b03
95. Hms3412d17
96. Hms3649j08
97. Hms3676d17
98. Hms3712l20
99. Hms3884d12
100. Mifepristone [orange Book]
101. 11.beta.-(p-(dimethylamino)phenyl)-17.beta.-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
102. Act02598
103. Bcp02145
104. Zinc3831128
105. Tox21_110952
106. Tox21_301841
107. Tox21_500801
108. Bdbm50072024
109. Hsci1_000369
110. S2606
111. Vx-410
112. Akos015895416
113. Tox21_110952_1
114. Ccg-101164
115. Ci-1073
116. Cs-1435
117. Db00834
118. Lp00801
119. Nc00414
120. Nsc 759862
121. Sdccgsbi-0050778.p002
122. Mifepristone 1.0 Mg/ml In Acetonitrile
123. Ncgc00025179-06
124. Ncgc00025179-07
125. Ncgc00025179-08
126. Ncgc00025179-09
127. Ncgc00025179-12
128. Ncgc00025179-13
129. Ncgc00025179-23
130. Ncgc00179632-01
131. Ncgc00255152-01
132. Ncgc00261486-01
133. (11beta,17beta)-11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one
134. As-13938
135. Cpd000058481
136. Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-, (11-beta,17-beta)-
137. Hy-13683
138. Ru486;c-1073
139. Eu-0100801
140. C07652
141. D00585
142. M 8046
143. 371m653
144. A840767
145. Q411240
146. Sr-01000721888
147. Q-201405
148. Sr-01000076011-1
149. Sr-01000076011-3
150. Sr-01000076011-5
151. Sr-01000076011-9
152. Sr-01000721888-4
153. Brd-k37270826-001-04-5
154. Brd-k37270826-001-31-8
155. Mifepristone, United States Pharmacopeia (usp) Reference Standard
156. (11?,17?)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one
157. 11.beta.-[4-(dimethylamino)phenyl]-17.beta.-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
158. 11beta-(4-dimethylamino)phenyl-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
159. 11ss-[p-(dimethylamino)fenyl]-17ss-hydroxy- 17-(1-propynyl)estra-4,9-dien-3-on
160. (10s,11s,14s,15s,17r)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-1,6-dien-5-one
161. (10s,11s,14s,15s,17r)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-5-one
162. (11.beta.,17.beta.)-11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one
163. (11r,13s,14s,17s)-11-(4-dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one
164. (8s,11r,13s,14s,17s)-11-[4-(dimethylamino)phenyl]-13-methyl-17-oxidanyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
165. 122742-25-0
166. 83203-42-3
167. Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propyn-1-yl)-, (11.beta.,17.beta.)-
168. Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-, (11b,17b)-
| Molecular Weight | 429.6 g/mol |
|---|---|
| Molecular Formula | C29H35NO2 |
| XLogP3 | 3.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 429.266779359 g/mol |
| Monoisotopic Mass | 429.266779359 g/mol |
| Topological Polar Surface Area | 40.5 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 921 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Korlym |
| PubMed Health | Mifepristone (By mouth) |
| Drug Classes | Antiglucocorticoid, Antiprogesterone |
| Drug Label | Korlym (mifepristone) is a cortisol receptor blocker for oral administration. The chemical name of mifepristone is 11-(4-dimethylaminophenyl)-17-hydroxy-17-(1-propynyl)-estra-4, 9-dien-3-one. The chemical formula is C29H35NO2; the molecular wei... |
| Active Ingredient | Mifepristone |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 300mg |
| Market Status | Prescription |
| Company | Corcept Therap |
| 2 of 4 | |
|---|---|
| Drug Name | Mifeprex |
| Active Ingredient | Mifepristone |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 200mg |
| Market Status | Prescription |
| Company | Danco Labs |
| 3 of 4 | |
|---|---|
| Drug Name | Korlym |
| PubMed Health | Mifepristone (By mouth) |
| Drug Classes | Antiglucocorticoid, Antiprogesterone |
| Drug Label | Korlym (mifepristone) is a cortisol receptor blocker for oral administration. The chemical name of mifepristone is 11-(4-dimethylaminophenyl)-17-hydroxy-17-(1-propynyl)-estra-4, 9-dien-3-one. The chemical formula is C29H35NO2; the molecular wei... |
| Active Ingredient | Mifepristone |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 300mg |
| Market Status | Prescription |
| Company | Corcept Therap |
| 4 of 4 | |
|---|---|
| Drug Name | Mifeprex |
| Active Ingredient | Mifepristone |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 200mg |
| Market Status | Prescription |
| Company | Danco Labs |
Abortifacient Agents, Steroidal; Contraceptives, Oral, Synthetic; Contraceptives, Postcoital, Synthetic; Hormone Antagonists; Luteolytic Agents; Menstruation-Inducing Agents
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
Mifepristone is indicated in combination with misoprostol for the medical termination of intrauterine pregnancy of 49 days duration or less. /Included in US product labeling/
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
Confirmed or suspected ectopic pregnancy, undiagnosed adnexal mass, or IUD currently in place. Chronic adrenal failure or concurrent long-term corticosteroid therapy. Known hypersensitivity to mifepristone, misoprostol, or other prostaglandins. Hemorrhagic disorders, inherited porphyrias, or concurrent anticoagulant therapy.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
Vaginal bleeding that is heavier than associated with a normal menses occurs in almost all women receiving mifepristone and misoprostol. Based on clinical studies, bleeding or spotting should be expected for an average of 9-16 days. ... Excessive bleeding may require treatment with vasoconstrictors, saline infusions, and/or blood transfusions or curettage.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
Severe vaginal bleeding may occur following spontaneous, surgical, or medical abortion (including following mifepristone administration). Prolonged heavy vaginal bleeding (i.e. soaking through 2 thick full-size sanitary pads per hour for 2 consecutive hours) may be a sign of incomplete abortion or other complications, and prompt medical or surgical intervention maybe required to prevent the development of hypovolemic shock. Patients should be advised to seek immediate medical attention if prolonged heavy vaginal bleeding or syncope occurs following mifepristone administration.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
Serious bacterial infections (including very rare cases of fatal septic shock) have been reported following mifepristone administration; a causal relationship to the mifepristone-misoprostol regimen has not been established. Clinicians should consider the possibility of infection if sustained fever (temperature of 38 degrees C or higher persisting for more than 4 hours), severe abdominal pain, or pelvic tenderness occurs within several days of medical abortion. Atypical presentations of serious infection and sepsis (i.e., presence of significant leukocytosis, tachycardia, or hemoconcentration without fever, severe abdominal pain, pelvic tenderness) may also occur.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
For more Drug Warnings (Complete) data for MIFEPRISTONE (14 total), please visit the HSDB record page.
For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.
FDA Label
Treatment of endometriosis
Treatment of hypercortisolism (Cushing's syndrome) of endogenous origin
Treatment of leiomyoma of uterus
Mifepristone is a synthetic steroid with antiprogestational effects indicated for the medical termination of intrauterine pregnancy through 49 days' pregnancy. Doses of 1 mg/kg or greater of mifepristone have been shown to antagonize the endometrial and myometrial effects of progesterone in women. During pregnancy, the compound sensitizes the myometrium to the contraction-inducing activity of prostaglandins. Mifepristone also exhibits antiglucocorticoid and weak antiandrogenic activity. The activity of the glucocorticoid dexamethasone in rats was inhibited following doses of 10 to 25 mg/kg of mifepristone. Doses of 4.5 mg/kg or greater in human beings resulted in a compensatory elevation of adrenocorticotropic hormone (ACTH) and cortisol.
Contraceptives, Oral, Synthetic
Oral contraceptives which owe their effectiveness to synthetic preparations. (See all compounds classified as Contraceptives, Oral, Synthetic.)
Luteolytic Agents
Chemical compounds that cause LUTEOLYSIS or degeneration of the CORPUS LUTEUM. (See all compounds classified as Luteolytic Agents.)
Contraceptives, Postcoital, Synthetic
Postcoital contraceptives which owe their effectiveness to synthetic preparations. (See all compounds classified as Contraceptives, Postcoital, Synthetic.)
Abortifacient Agents, Steroidal
Steroidal compounds with abortifacient activity. (See all compounds classified as Abortifacient Agents, Steroidal.)
Menstruation-Inducing Agents
Chemical compounds that induce menstruation either through direct action on the reproductive organs or through indirect action by relieving another condition of which amenorrhea is a secondary result. (From Dorland, 27th ed) (See all compounds classified as Menstruation-Inducing Agents.)
Hormone Antagonists
Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. (See all compounds classified as Hormone Antagonists.)
G03XB01
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
G - Genito urinary system and sex hormones
G03 - Sex hormones and modulators of the genital system
G03X - Other sex hormones and modulators of the genital system
G03XB - Progesterone receptor modulators
G03XB01 - Mifepristone
Absorption
The absolute bioavailability of a 20 mg oral dose is 69%
Route of Elimination
Fecal: 83%; Renal: 9%.
The absolute bioavailability of oral mifepristone is 69%.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
Protein binding: Very high (98%); predominantly to albumin and alpha1- acid glycoprotein.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
Time to peak concentration: 90 minutes after a 600 mg oral dose.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
Peak plasma concentration: 1.98 mg/L following a single 600 mg oral dose.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
Fecal; 83% of a 600 mg dose over 11 days. Renal; 9% of a 600 mg dose over 11 days.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
Hepatic. Hepatic, by Cytochrome P450 3A4 isoenzyme to the N-monodemethylated metabolite (RU 42 633); RU 42 698, which results from the loss of two methyl groups from position 11 beta; and RU 42 698, which results from terminal hydroxylation of the 17–propynyl chain.
Hepatic, by Cytochrome P450 3A4 isoenzyme to the N-monodemethylated metabolite (RU 42 633); RU 42 698, which results from terminal hydroxylation of the 17-propynyl chain.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
Mifepristone has known human metabolites that include 17alpha-hydroxymifepristone and Monodemethylated mifepristone.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
18 hours
Terminal: 18 hours; begins slowly and becomes more rapid with time.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
The anti-progestational activity of mifepristone results from competitive interaction with progesterone at progesterone-receptor sites. Based on studies with various oral doses in several animal species (mouse, rat, rabbit and monkey), the compound inhibits the activity of endogenous or exogenous progesterone. The termination of pregnancy results. In the treatment of Cushing's syndrome, Mifepristone blocks the binding of cortisol to its receptor. It does not decrease cortisol production but reduces the effects of excess cortisol, such as high blood sugar levels.
Mifepristone competitively inhibits the actions of progesterone at progesterone-receptor sites, resulting in termination of pregnancy.The combination of mifepristone and misoprostol causes expulsion of the products of conception through decidual necrosis, myometrial contractions, and cervical softening.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
When administered in the early stages of pregnancy, mifepristone causes decidual breakdown by blockade of uterine progesterone receptors. This leads to detachment of the blastocyte, which decreases hCG production. This in turn causes a decrease in progesterone secretion from the corpus luteum, which further accentuates decidual breakdown. Decreased endogenous progesterone coupled with blockade of progesterone receptors in the uterus increases prostaglandin levels and sensitizes the myometrium to the contractile actions of prostaglandins.
Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 1622
In addition, mifepristone promotes uterine contractions and softening of the cervix and sensitizes the myometrium to effects of prostaglandins (e.g., misoprostol) that stimulate uterine contraction and expulsion of the products of conception. In the absence of progesterone, mifepristone acts as a partial progestin agonist. At dosages higher than those used for termination of pregnancy, mifepristone also exhibits antiglucocorticoid activity. The drug also has been shown to have weak antiandrogenic activity.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37250
Submission : 2022-06-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-05-24
Pay. Date : 2013-09-12
DMF Number : 27474
Submission : 2013-09-13
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37121
Submission : 2022-05-12
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24628
Submission : 2011-01-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21944
Submission : 2008-09-08
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2017-11-16
Pay. Date : 2017-08-21
DMF Number : 31873
Submission : 2017-07-20
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]JDMF
Registration Number : 302MF10146
Registrant's Address : Parque Tecnologico-Parcela 105 Boecillo (Valladolid) Spain
Initial Date of Registration : 2020-12-15
Latest Date of Registration : 2020-12-15
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
Date of Issue : 2022-08-08
Valid Till : 2025-07-14
Written Confirmation Number : WC-0168
Address of the Firm : Plot No. 24/2, & 25, Phase -IV, GIDC Industrial Zone, At & Post - Panoli, Dist.-...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
NDC Package Code : 68925-0007
Start Marketing Date : 2011-01-28
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 69989-0003
Start Marketing Date : 2008-09-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/1)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 65089-0043
Start Marketing Date : 2000-09-28
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 66499-0056
Start Marketing Date : 2013-08-23
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 51508-011
Start Marketing Date : 2022-03-04
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 83914-003
Start Marketing Date : 2025-02-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 44132-005
Start Marketing Date : 2012-06-08
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 44132-013
Start Marketing Date : 2014-06-17
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 60722-3002
Start Marketing Date : 2020-10-23
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
Gonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.
About the Company : Gonane Pharma is a contract pharmaceutical company based in Gujarat, India, specializing in the manufacturing and marketing of corticosteroids, hormones, antivirals, and oncology p...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for pharmaceutical and biotech industries. LGM also operates as a full-service CDMO, offering formulat...
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
About the Company : Founded in 2003, Seqens has evolved into a global leader in pharmaceutical solutions and specialty ingredients. The company supports customers in the development, scale-up, and man...
About the Company : Arudavis Labs is in the business of manufacturing and trading of Active Pharmaceutical Ingredients and Formulations. We have been serving the Pharmaceutical and Biotechnology Indus...
About the Company : ASG Biochem Private Limited at Ganganagar near Kolkata, West Bengal, India, is a bulk API manufacturing company of the New Delhi based diversified APEEJAY STYA GROUP. The unit acqu...
About the Company : Balaji corporation was established in 2006, the group have two branch in india.To play a key role as innovative and delenadable service provided.The company was quick to envisage t...
About the Company : Curia is a global contract research, development and manufacturing organization (CDMO), offering products and services across the drug development spectrum to help our partners tur...
About the Company : Formosa Laboratories Inc. founded in Taiwan since 1995 started with API business and has been serving customers worldwide. As an established API manufacturer receiving GMP inspecti...
About the Company : Hanways Chempharm Co., Limited, the former one is Hubei Hanways Pharchem CO.,Limited, set up in 2009 in Wuhan, China. We are engaged in supplying APIs, pharmaceutical intermediate...
About the Company : NAARI, meaning woman in Sanskrit, embodies the philosophy and objectives of our Organization. NAARI is a Swiss Pharmaceuticals company focused on female health with an emphasis on...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Korlym (mifepristone) is a selective antagonist of the progesterone receptor at low doses and blocks the GR-II at higher doses. It is being evaluated for the treatment of cushing syndrome.
Lead Product(s): Mifepristone,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Korlym
Study Phase: Phase IVProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 12, 2024
Lead Product(s) : Mifepristone,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Corcept Announces Positive CATALYST Trial Results in Hypercortisolism and Diabetes
Details : Korlym (mifepristone) is a selective antagonist of the progesterone receptor at low doses and blocks the GR-II at higher doses. It is being evaluated for the treatment of cushing syndrome.
Product Name : Korlym
Product Type : Hormone
Upfront Cash : Inapplicable
December 12, 2024
Details:
Mifepristone is a Hormone drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Stress Disorders, Post-Traumatic.
Lead Product(s): Mifepristone,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Hormone
Sponsor: Christiaan Vinkers
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 14, 2024
Lead Product(s) : Mifepristone,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Christiaan Vinkers
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mifepristone is a Hormone drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Stress Disorders, Post-Traumatic.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
November 14, 2024
Details:
Progesterone is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Progesterone Supplementation After Mifepristone.
Lead Product(s): Progesterone,Mifepristone
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 27, 2024
Lead Product(s) : Progesterone,Mifepristone
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Endometrial Transcript Profile with Progesterone After Post-ovulatory Mifepristone
Details : Progesterone is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Progesterone Supplementation After Mifepristone.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
September 27, 2024
Details:
Levonorgestrel is a Hormone drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Pregnancy, Early.
Lead Product(s): Levonorgestrel,Mifepristone
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Hormone
Sponsor: Cuidado Integral de la Mujer, Gineclinic, S.C. | Servicios de Salud Medieg, A. C
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 09, 2024
Lead Product(s) : Levonorgestrel,Mifepristone
Therapeutic Area : Undisclosed
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Cuidado Integral de la Mujer, Gineclinic, S.C. | Servicios de Salud Medieg, A. C
Deal Size : Inapplicable
Deal Type : Inapplicable
Assessing the Efficacy and Acceptability of Two Missed Period Pills Regimens
Details : Levonorgestrel is a Hormone drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Pregnancy, Early.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
July 09, 2024
Details:
Korlym (mifepristone) is an approved selective antagonist of the progesterone receptor at low doses and blocks the GR-II at higher doses. It is being evaluated in phase 4 for cushing syndrome.
Lead Product(s): Mifepristone,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Korlym
Study Phase: Phase IVProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 29, 2024
Lead Product(s) : Mifepristone,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Corcept Completes Enrollment in Phase 4 CATALYST Trial
Details : Korlym (mifepristone) is an approved selective antagonist of the progesterone receptor at low doses and blocks the GR-II at higher doses. It is being evaluated in phase 4 for cushing syndrome.
Product Name : Korlym
Product Type : Hormone
Upfront Cash : Inapplicable
April 29, 2024
Details:
Korlym (mifepristone) blocks cortisol receptors to manage hyperglycemia in adults with Cushing's syndrome who have type 2 diabetes or glucose intolerance.
Lead Product(s): Mifepristone,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Korlym
Study Phase: Phase IVProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 15, 2024
Lead Product(s) : Mifepristone,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
Details : Korlym (mifepristone) blocks cortisol receptors to manage hyperglycemia in adults with Cushing's syndrome who have type 2 diabetes or glucose intolerance.
Product Name : Korlym
Product Type : Hormone
Upfront Cash : Inapplicable
February 15, 2024
Details:
Korlym (mifepristone) is a selective antagonist of the progesterone receptor at low doses and blocks the GR-II at higher doses. It is being evaluated for the treatment of cushing syndrome.
Lead Product(s): Mifepristone,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Korlym
Study Phase: Phase IVProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 15, 2024
Lead Product(s) : Mifepristone,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
Details : Korlym (mifepristone) is a selective antagonist of the progesterone receptor at low doses and blocks the GR-II at higher doses. It is being evaluated for the treatment of cushing syndrome.
Product Name : Korlym
Product Type : Hormone
Upfront Cash : Inapplicable
February 15, 2024
Details:
FloraStilbene (mifepristone and pterostilbene) aims to stimulate the immune system in advanced breast cancer patients, with preclinical data showing efficacy in a triple-negative breast cancer model.
Lead Product(s): Mifepristone,Pterostilbene
Therapeutic Area: Oncology Brand Name: FloraStilbene
Study Phase: Phase IProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 03, 2024
Lead Product(s) : Mifepristone,Pterostilbene
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Therapeutic Solutions’ Res Nova Bio Reports Positive Data in Advanced Cancer
Details : FloraStilbene (mifepristone and pterostilbene) aims to stimulate the immune system in advanced breast cancer patients, with preclinical data showing efficacy in a triple-negative breast cancer model.
Product Name : FloraStilbene
Product Type : Hormone
Upfront Cash : Inapplicable
January 03, 2024
Details:
FloraStilbene (RU486 and pterostilbene) to stimulate the immune system in advanced breast cancer patients. Preclinical data demonstrated that FloraStilbene overcame immune suppression induced in the 4T1 mouse model of triple negative breast cancer.
Lead Product(s): Mifepristone,Pterostilbene
Therapeutic Area: Oncology Brand Name: FloraStilbene
Study Phase: Phase IProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 20, 2023
Lead Product(s) : Mifepristone,Pterostilbene
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Res Nova Biologics Announces First Cancer Patient Treated with FloraStilbene™
Details : FloraStilbene (RU486 and pterostilbene) to stimulate the immune system in advanced breast cancer patients. Preclinical data demonstrated that FloraStilbene overcame immune suppression induced in the 4T1 mouse model of triple negative breast cancer.
Product Name : FloraStilbene
Product Type : Hormone
Upfront Cash : Inapplicable
October 20, 2023
Details:
Under the collaboration, Cure Stat Rx will manufacture first in class breast cancer immunotherapy product FloraStilbene™ for a planned 12 patient Phase I/II trial aimed at assessing immunomodulatory activity of the drug candidate in advanced breast cancer patients.
Lead Product(s): Mifepristone,Pterostilbene
Therapeutic Area: Oncology Brand Name: FloraStilbene
Study Phase: PreclinicalProduct Type: Hormone
Sponsor: Cure Stat Rx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 15, 2023
Lead Product(s) : Mifepristone,Pterostilbene
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Cure Stat Rx
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, Cure Stat Rx will manufacture first in class breast cancer immunotherapy product FloraStilbene™ for a planned 12 patient Phase I/II trial aimed at assessing immunomodulatory activity of the drug candidate in advanced breast can...
Product Name : FloraStilbene
Product Type : Hormone
Upfront Cash : Undisclosed
May 15, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
CAS Number : 39416-48-3
End Use API : Mifepristone
About The Company : NINGBO INNO PHARMCHEM CO.,LTD. develop, pilot and commercial produce organic chemicals, pharmaceutical intermediates and nutraceuticals. We also offer custom sy...
19-nor-5(10)-androstene-3,17-dione
CAS Number : 3962-66-1
End Use API : Mifepristone
About The Company : With the high technology and excellent services, Xianju pharma earned a top worldwide reputation for quality in pharmaceutical industry. Xianju pharma has dedic...
3-ethylene dioxy-17-oxo-13ß-methyl-estra-5(10),9(...
CAS Number : 24916-90-3
End Use API : Mifepristone
About The Company : With the high technology and excellent services, Xianju pharma earned a top worldwide reputation for quality in pharmaceutical industry. Xianju pharma has dedic...
5a,10a-epoxy-3,3-ethylenedioxy-17a-propynyl-estra-...
CAS Number : 84371-57-3
End Use API : Mifepristone
About The Company : With the high technology and excellent services, Xianju pharma earned a top worldwide reputation for quality in pharmaceutical industry. Xianju pharma has dedic...
3-(1,2-ethanediyl-bosoxy)-11a-(4-(n,n- dimethylami...
CAS Number : 84371-64-2
End Use API : Mifepristone
About The Company : With the high technology and excellent services, Xianju pharma earned a top worldwide reputation for quality in pharmaceutical industry. Xianju pharma has dedic...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Keval Exports
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nitika Pharmaceutical Specialities
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Silverline Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Coating Systems & Additives
Fillers, Diluents & Binders
Controlled & Modified Release
Disintegrants & Superdisintegrants
Thickeners and Stabilizers
Lubricants & Glidants
Granulation
Solubilizers
Direct Compression
Film Formers & Plasticizers
Co-Processed Excipients
Taste Masking
Emulsifying Agents
Parenteral
API Stability Enhancers
Empty Capsules
Vegetarian Capsules
Surfactant & Foaming Agents
Topical
Chewable & Orodispersible Aids
Rheology Modifiers
Coloring Agents
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
13
PharmaCompass offers a list of Mifepristone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Mifepristone manufacturer or Mifepristone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Mifepristone manufacturer or Mifepristone supplier.
PharmaCompass also assists you with knowing the Mifepristone API Price utilized in the formulation of products. Mifepristone API Price is not always fixed or binding as the Mifepristone Price is obtained through a variety of data sources. The Mifepristone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Mifepristone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mifepristone, including repackagers and relabelers. The FDA regulates Mifepristone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mifepristone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Mifepristone manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Mifepristone supplier is an individual or a company that provides Mifepristone active pharmaceutical ingredient (API) or Mifepristone finished formulations upon request. The Mifepristone suppliers may include Mifepristone API manufacturers, exporters, distributors and traders.
click here to find a list of Mifepristone suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Mifepristone DMF (Drug Master File) is a document detailing the whole manufacturing process of Mifepristone active pharmaceutical ingredient (API) in detail. Different forms of Mifepristone DMFs exist exist since differing nations have different regulations, such as Mifepristone USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Mifepristone DMF submitted to regulatory agencies in the US is known as a USDMF. Mifepristone USDMF includes data on Mifepristone's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Mifepristone USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Mifepristone suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Mifepristone Drug Master File in Japan (Mifepristone JDMF) empowers Mifepristone API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Mifepristone JDMF during the approval evaluation for pharmaceutical products. At the time of Mifepristone JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Mifepristone suppliers with JDMF on PharmaCompass.
A Mifepristone written confirmation (Mifepristone WC) is an official document issued by a regulatory agency to a Mifepristone manufacturer, verifying that the manufacturing facility of a Mifepristone active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Mifepristone APIs or Mifepristone finished pharmaceutical products to another nation, regulatory agencies frequently require a Mifepristone WC (written confirmation) as part of the regulatory process.
click here to find a list of Mifepristone suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Mifepristone as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Mifepristone API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Mifepristone as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Mifepristone and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Mifepristone NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Mifepristone suppliers with NDC on PharmaCompass.
Mifepristone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Mifepristone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Mifepristone GMP manufacturer or Mifepristone GMP API supplier for your needs.
A Mifepristone CoA (Certificate of Analysis) is a formal document that attests to Mifepristone's compliance with Mifepristone specifications and serves as a tool for batch-level quality control.
Mifepristone CoA mostly includes findings from lab analyses of a specific batch. For each Mifepristone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Mifepristone may be tested according to a variety of international standards, such as European Pharmacopoeia (Mifepristone EP), Mifepristone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Mifepristone USP).
